Open Close

Sparton inks deal to make bacterial identification system for PathoGenetix

PathoGenetix, Inc. said has signed Sparton Corp. (NYSE: SPA) as the design and manufacturing partner for the Resolution Microbial Genotyping System.

Under the terms of the agreement, Sparton will conduct design for manufacture and pilot production of a limited number of pre-commercial instruments for the Resolution System, which is slated for commercial availability in the fourth quarter of 2014.

The Resolution System is the first commercial application of PathoGenetix´s proprietary genome sequence scanning technology.

Sparton is a premier partner in the design as well as full production manufacture of class I, II, and III instruments for highly specialized medical, biotechnology, and life science technologies.

PathoGenetix is a commercial-stage developer of an automated system for rapid bacterial identification from complex samples. Learn more at

Sparton, now in its 114th year, is a provider of complex and sophisticated electromechanical devices with capabilities that include concept development, industrial design, design and manufacturing engineering, production, distribution, field service, and refurbishment. Its website is at


If you enjoyed this post, please consider leaving a comment or subscribing to the RSS feed to have future articles delivered to your feed reader.